Mercuria Capital Strategies LLC Takes Position in Drugs Made In America Acquisition Corp. $DMAA

Posted by Brenda Bartman on Jun 7th, 2026

Mercuria Capital Strategies LLC bought a new stake in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 750,000 shares of the company’s stock, valued at approximately $7,511,000. Drugs Made In America Acquisition accounts for approximately 6.2% of Mercuria Capital Strategies LLC’s investment portfolio, making the stock its 6th biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Wolverine Asset Management LLC boosted its stake in shares of Drugs Made In America Acquisition by 4.7% in the 4th quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock valued at $13,564,000 after purchasing an additional 58,340 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Drugs Made In America Acquisition in the 2nd quarter valued at $5,814,000. Radcliffe Capital Management L.P. boosted its stake in shares of Drugs Made In America Acquisition by 316.7% in the 3rd quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock valued at $5,424,000 after purchasing an additional 401,378 shares in the last quarter. Context Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition in the 3rd quarter valued at $2,568,000. Finally, Clear Street Group Inc. acquired a new stake in shares of Drugs Made In America Acquisition in the 3rd quarter valued at $2,152,000.

Drugs Made In America Acquisition Stock Performance

Drugs Made In America Acquisition stock opened at $10.61 on Friday. Drugs Made In America Acquisition Corp. has a 1 year low of $10.15 and a 1 year high of $10.62. The company’s 50-day moving average is $10.56 and its two-hundred day moving average is $10.46.

Drugs Made In America Acquisition (NASDAQ:DMAA – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported $0.06 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Get Our Latest Analysis on Drugs Made In America Acquisition

Drugs Made In America Acquisition Company Profile

(Free Report)

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.